Chapuy Bjoern, Roemer Margaretha G M, Stewart Chip, Tan Yuxiang, Abo Ryan P, Zhang Liye, Dunford Andrew J, Meredith David M, Thorner Aaron R, Jordanova Ekaterina S, Liu Gang, Feuerhake Friedrich, Ducar Matthew D, Illerhaus Gerald, Gusenleitner Daniel, Linden Erica A, Sun Heather H, Homer Heather, Aono Miyuki, Pinkus Geraldine S, Ligon Azra H, Ligon Keith L, Ferry Judith A, Freeman Gordon J, van Hummelen Paul, Golub Todd R, Getz Gad, Rodig Scott J, de Jong Daphne, Monti Stefano, Shipp Margaret A
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands;
Blood. 2016 Feb 18;127(7):869-81. doi: 10.1182/blood-2015-10-673236. Epub 2015 Dec 23.
Primary central nervous system lymphomas (PCNSLs) and primary testicular lymphomas (PTLs) are extranodal large B-cell lymphomas (LBCLs) with inferior responses to current empiric treatment regimens. To identify targetable genetic features of PCNSL and PTL, we characterized their recurrent somatic mutations, chromosomal rearrangements, copy number alterations (CNAs), and associated driver genes, and compared these comprehensive genetic signatures to those of diffuse LBCL and primary mediastinal large B-cell lymphoma (PMBL). These studies identify unique combinations of genetic alterations in discrete LBCL subtypes and subtype-selective bases for targeted therapy. PCNSLs and PTLs frequently exhibit genomic instability, and near-uniform, often biallelic, CDKN2A loss with rare TP53 mutations. PCNSLs and PTLs also use multiple genetic mechanisms to target key genes and pathways and exhibit near-uniform oncogenic Toll-like receptor signaling as a result of MYD88 mutation and/or NFKBIZ amplification, frequent concurrent B-cell receptor pathway activation, and deregulation of BCL6. Of great interest, PCNSLs and PTLs also have frequent 9p24.1/PD-L1/PD-L2 CNAs and additional translocations of these loci, structural bases of immune evasion that are shared with PMBL.
J Transl Med. 2024-5-1
Neuropathol Appl Neurobiol. 2016-4
Clin Cancer Res. 2012-7-26
Clin Pharmacol. 2025-5-28
Proc Natl Acad Sci U S A. 2015-3-10
Nat Rev Immunol. 2015-3
N Engl J Med. 2014-12-6
Nucleic Acids Res. 2015-2-18
J Clin Invest. 2014-11
Oncotarget. 2014-7-15